- Oral presentation
- Open Access
Chemotherapeutics for vivax malaria
Malaria Journal volume 11, Article number: O21 (2012)
Plasmodium vivax imposes significant burdens of morbidity and mortality across the malaria endemic world. Treatment of this infection requires a blood schizontocide against the acute attack and hypnozoitocide against relapses. Chloroquine combined with primaquine has been the therapy of choice for radical cure of vivax malaria since the 1950s. Primaquine, however, was never optimized or adapted for use in endemic zones and its toxicity in prevalent G6PD-defkient patients (typically 5-20%) sharply limits its effectiveness. Resistance to chloroquine has emerged in Southeast Asia and now threatens the Indian sub-continent where most P. vivax occurs. The research community faces the steep challenge of developing new radical cure strategies. This presentation explores those challenges and the means to meet them, principally optimizing primaquine as a partner to new ACTs for maximum efficacy and more practical dosing and safety.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Baird, J.K. Chemotherapeutics for vivax malaria. Malar J 11 (Suppl 1), O21 (2012). https://doi.org/10.1186/1475-2875-11-S1-O21
- Infectious Disease
- Research Community